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In the past four decades, substantial progress has been made in breast cancer survival in part 
because of advances in early detection and treatment following diagnosis.1,2 Further, recent 
studies3,4 have reported that the observed improvement in breast cancer mortality and 
survival between the 1970s and 2000s is also the result of changes in the distribution of 
tumor characteristics, which include the identification of the human epidermal growth factor 
receptor 2 and the development of the targeted agent such as trastuzumab that extends 
survival in both the adjuvant and metastatic settings for a range of 15%–25% of patients 
with human epidermal growth factor receptor 2–positive tumors. For example, in 2012, the 
annual age-adjusted breast cancer mortality was approximately 21 per 100,000 and 5-year 
relative survival exceeded 90%.5 Despite this progress, not all age, racial/ethnic, or 
socioeconomic groups have benefited equally, and disparities in incidence and mortality still 
exist.6 During the past four decades, incidence of breast cancer was much higher in older 
women (aged >50 years) and the survival rate was lower in younger women (aged <50 
years).7 This is in part because breast cancer in women aged 15–44 years (henceforth 
referred to as younger women) is often characterized by aggressive tumor subtypes that are 
less likely to be amenable to treatment at the time of diagnosis and have poorer survival 
outcomes.8–11 As a result, these breast cancers could result in more devastating health 
outcomes and economic burden to younger women, their families, and society.
In recent years, there has been increased interest in breast cancer among younger women. In 
2009, the Education and Awareness Requires Learning Young Act, which is presented in 
detail in Section 10413 of the Patient Protection and Affordable Care Act,12 authorized CDC 
to conduct research and develop initiatives that increase knowledge in evidence-based 
approaches to advance understanding and awareness of breast health and breast cancer 
among younger women. To provide information to support resource allocation decisions that 
effectively increase awareness and support among younger women diagnosed with breast 
cancer, the authors set out to quantify the economic burden in this population. To date, there 
have been no national studies specifically quantifying the economic burden of breast cancer 
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in younger women in the U.S. The available estimates are at the aggregate level regardless of 
specific age group. For instance, a study13 reported economic burden on breast cancer care 
for all women to be $16.5 billion in 2010 dollars. Although these are useful data for decision 
making, they mask information on the burden of breast cancer outcomes and economic costs 
in younger women. Therefore, gaps exist in knowledge about the health outcomes and 
economic burden of breast cancer in this population. Historically, economic burden studies 
have proven to be useful for providing a basis for decision making in program planning and 
evaluating interventions such as cancer screening programs.
The five articles in this theme issue attempt to address the economic burden of breast cancer 
among younger women. In this issue, economic burden was defined as changes in health-
related quality of life (HRQoL), a measure of resources used for medical care and loss of 
economic resources associated with the diagnosis and treatment of breast cancer in this 
population. Given this definition, the articles presented in this theme issue consist of two 
categories:
1. assessment of health outcomes; and
2. assessment of economic impacts.
Figure 1 illustrates the conceptual framework of how the articles fit together to provide up-
to-date data that could be used to inform budget, clinical, and health promotion decisions in 
this population.
The first two articles address issues on health outcomes that reflect women’s self-assessment 
of the impact of breast cancer treatment(s) on their HRQoL and well-being. The article by 
Brown et al.14 provides new and important data on the burden of breast cancer in younger 
women for use in the economic evaluation of intervention programs and public health 
surveillance. The authors used a measure known as the health state utility (HSU), a cardinal 
scale that represents a 0 (worst health) to 1 (best health) summary of preference-weighted 
outcomes over HRQoL outcomes. They found that the burden of breast cancer in terms of 
HSU was significantly larger for younger women compared with women aged ≥45 years. 
Additionally, the HSU impact on breast cancer was significantly larger than that found for 
other types of cancer. These differences underscore the importance of conducting age-
specific analysis when measuring HRQoL and HSU values in economic evaluation of public 
health programs and when making medical decisions for cancer treatment among younger 
women. The results also suggest that clinicians and public health officials should consider 
placing greater emphasis on identification of preventive measures for younger women who 
may be at greater risk for breast cancer, as the HRQoL burden for a woman aged <45 years 
is significantly larger than that caused by other cancers.
The second article by Trogdon and colleagues15 complements Brown et al.14 by further 
examining the HRQoL impacts of breast cancer, measured by HSU, age of diagnosis, and 
race/ethnicity. Prior to this paper, little was known about the effect of breast cancer diagnosis 
on HRQoL among younger women. The existing literature suggests that younger women 
with breast cancer may face substantial HRQoL challenges, including chemotherapy-
induced menopause, decreased sexual function, infertility, diminished body image, and other 
side effects.16–19 There is also evidence that the HRQoL effects of breast cancer vary by 
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race/ethnicity.20–24 Trogdon and colleagues15 reported three key findings. First, the HRQoL 
effects of breast cancer are larger among women diagnosed at younger ages. Second, the 
HRQoL effects of breast cancer are concentrated in the first year after diagnosis, with larger 
effects among women diagnosed at younger ages. Third, there are significant differences in 
the HRQoL effects of breast cancer by race/ethnicity. The results highlight the need for 
separate quality of life adjustments for women by age at diagnosis and race/ethnicity when 
conducting cost-effectiveness analysis of breast cancer prevention, detection, and treatment.
The last three articles assessed economic impacts and described the direct medical care costs 
consumed in treating breast cancer and indirect morbidity costs associated with the 
diagnosis of breast cancer in this population. Two of the articles focused on direct medical 
care costs: Allaire et al.25 examined medical care costs of breast cancer in privately insured 
younger women, and Ekwueme and colleagues26 presented estimates of treatment costs of 
breast cancer among younger women enrolled in Medicaid. The last article in the series by 
Ekwueme et al.27 focused on indirect morbidity costs and presented estimates of 
productivity costs associated with younger breast cancer survivors. The cost estimates 
reported in these three articles are prevalence-based, which represent economic cost burden 
for all young women breast cancer survivors alive in a specific year. Prevalence cost 
estimates can be useful for informing the design of insurance benefits, eligibility criteria for 
public programs, and budgeting for future program costs.28
The study by Allaire and colleagues25 utilized the MarketScan database, which contains one 
of the nation’s largest administrative claims data on people who have employment-based 
health insurance. The database included de-identified, person-specific outpatient, inpatient, 
and retail pharmaceutical claims from approximately 100 large payers, representing millions 
of covered lives.29 Treatment costs for younger breast cancer patients were compared with a 
matched sample of younger women without breast cancer and for those in active treatment. 
Allaire et al.25 found that younger women incurred >$24,000 in additional direct medical 
care costs per person per year compared with younger women without breast cancer. The 
reported treatment cost was twice higher (>$52,000) for those in active treatment. Also, they 
found that nearly all (96%) of these costs occurred in an outpatient setting. These estimates 
indicate that breast cancer is a costly illness to treat among younger, privately insured 
women. The findings underscore the potential financial vulnerability of women in this age 
group and the importance of health insurance during this time in life.
The second medical care costs article by Ekwueme and colleagues26 used Medicaid Analytic 
eXtract claims and enrollment data maintained by the Centers for Medicare and Medicaid 
Services containing information from 50 states and the District of Columbia. The study 
sample was women ages 19–44 enrolled in fee-for-service Medicaid. Because much of the 
Medicaid Analytic eXtract population was enrolled in Medicaid for less than a full calendar 
year, the authors reported monthly Medicaid payments to accurately reflect the healthcare 
needs for each woman. The estimates were reported by mutually exclusive racial/ethnic 
categories and by service types. The estimates were compared with the same age group 
without breast cancer. The analysis found that monthly direct medical cost for breast cancer 
treatment among younger women enrolled in Medicaid was $5,711 per woman. The monthly 
cost for outpatient and inpatient services was $4,058 and $1,003, respectively, and 
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prescription drug costs were $539. By race/ethnicity, the authors found that non-Hispanic 
white women had the highest monthly total medical costs, followed by Hispanic women, 
and then non-Hispanic women of other race. These findings can inform future planning for 
treatment cost of invasive breast cancer in low-income younger women enrolled in 
Medicaid.
The final article in this theme collection by Ekwueme et al.27 focused on productivity costs 
associated with younger breast cancer survivors. This article is based on the premise that 
cancer diagnosis and treatment may have variable effects on employment. Even if younger 
women who have survived do not become unemployed, there may be a degree of 
underemployment or loss of income. This issue has been poorly quantified in the literature, 
especially for younger cancer survivors, who are more at risk for longer and late effects of 
cancer treatment. The authors used a nationally representative sample from the National 
Health Interview Survey, 2000–2010, to address the following questions:
1. What are the costs of forgone earnings from missed work days associated with 
breast cancer for employed women?
2. What are the costs of lost home productivity associated with breast cancer?
3. How do the breast cancer–associated productivity costs among younger survivors 
compare with those of older survivors aged 45–64 years?
They found that work loss costs were higher per capita among younger employed women 
than older employed women. In general, the study showed that younger women with a 
history of breast cancer face a disproportionate share of work and home productivity losses. 
The authors postulated that this finding may be explained by the fact that breast cancer in 
younger women is often more severe, requiring more-aggressive treatment that can 
precipitate a range of physical, functional, and psychosocial long-term and late effects, 
leading to more frequent and longer absenteeism from work.30,31
Applications of the Findings
The set of articles presented in this issue have several applications. First, one of the primary 
goals of disease prevention is to improve HRQoL outcomes of affected individuals. 
However, efforts to improve HRQoL may involve a patient being treated with many cancer 
treatments such as surgery, chemotherapy, radiation, and hormonal therapy. These treatment 
regimens are associated with late and long-term health effects such as cardiotoxicity, 
lymphedema, sexual dysfunction, incontinence, pain and fatigue, cognitive dysfunction, and 
psychological distress.32 The findings in this theme issue provide data on women’s self-
assessment of how breast cancer treatments have affected their lives and well-being. This is 
important information that could be used for evaluating treatment efficacy and effectiveness 
and interpreting clinical outcomes of breast cancer treatment in younger women. Further, the 
findings could be used to conduct cost-effectiveness or cost-utility analysis of breast cancer 
on primary, secondary, or tertiary prevention programs in this population.33
Second, there are multiple uses for economic data reported in this theme collection; 
however, most of the applications may center on two broad categories:
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1. assessment of economic burden; and
2. economic evaluation of specific breast cancer interventions.
In the first category, the cost estimates in this issue take a national-level perspective, which 
means that the reported findings could be used to inform decisions on resource allocation in 
breast cancer prevention at the national level. Further, given the substantial productivity 
losses associated with breast cancer among younger women, the reported findings could 
inform the potential value of developing interventions to reduce side effects associated with 
cancer treatment. Many young women are surviving breast cancer, but these survivors face 
many challenges with medical care follow-up, managing the long-term and late effects of 
treatments,34 monitoring the possibility of recurrence, and an increased risk for additional 
cancers.34,35 In addition, as reported in this issue, these women experience limitations in 
their HRQoL.14,15
In the second category, the reported data in this issue can directly be used as inputs to 
conduct economic evaluations of specific healthcare interventions or programs related to 
breast cancer in younger women. For example, these findings can be used in estimating the 
cost-effectiveness or cost-utility analysis of breastfeeding as a primary prevention for breast 
cancer in younger women privately insured or publicly insured through Medicaid. In this 
example, the medical care costs data from privately insured reported by Allaire and 
colleagues25 and from Medicaid enrollees reported by Ekwueme et al.,26 along with the 
reported health outcomes by Brown and colleagues14 and Trogdon et al.,15 can be used to 
estimate the cost effectiveness of this intervention either in privately or publically insured 
women compared with two or more alternative programs. Similarly, an analyst could also 
use the presented cost data to conduct a budget impact analysis to appraise the financial 
impact and the feasibility and affordability of breastfeeding interventions in this population.
Implications for Prevention Programs
From a public health perspective, the data reported in this collection of papers could be used 
to effectively develop or evaluate intervention programs in this population. For example, 
CDC is implementing a program on “multiple approaches to increase awareness and support 
among young women diagnosed with breast cancer.”36 This program is designed to develop 
a strategic and integrated health communication, marketing, and media approach to 
disseminating health messages to young women breast cancer survivors and to provide 
structured support services from diagnosis through post treatment. As this program is being 
implemented, the reported findings in this issue could provide information on the magnitude 
of economic burden of breast cancer on subpopulations of young women facing the disease. 
This information can potentially inform the allocation of resources to subgroups with 
disproportionate burden and effectively channel targeted interventions to this group.
In addition to the new program, CDC has recently launched a multimedia national campaign 
with the objectives to educate young women on the risk factors for breast cancer before age 
45 years, encourage them to learn their family history of breast and ovarian cancer, inspire 
them to talk to their healthcare provider if they think they might be at higher risk for breast 
cancer, and encourage them to live healthy lifestyles and be aware of their own breast health.
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 Implementing these objectives could save as well as improve the lives of these women 
and subsequently reduce the substantial loss in HRQoL and the huge economic burden 
reported in this theme issue. Because these women are at working age, a cancer diagnosis 
and subsequent treatment(s) may interrupt employment and have a lasting negative impact 
on present and future earnings, career development, and perhaps retirement decisions. 
Therefore, efforts to prevent breast cancer by raising awareness and risk reduction strategies 
such as maintaining physical activity through childhood, adolescence, and adult years38; 
increasing breastfeeding rates for a reasonable length of time39; and, for high-risk women, 
increasing access to prophylactic treatment such as surgery or use of medications like 
tamoxifen40,41 could eventually improve health outcomes and economic outlook in this 
population. These primary prevention measures are essential, particularly for younger 
women aged 18–44 years for whom early detection through screening is not recommended.
42
Moving Forward
Together, the papers presented in this theme issue provide health outcomes and economic 
cost data needed to make informed clinical and health promotion decisions related to breast 
cancer among younger women. With the availability of these data, healthcare decision 
makers, public health programs, and researchers will have state-of-the-art economic burden 
data on breast cancer among younger women to support prevention activities.
While moving forward to ascertain the health outcomes and economic burden of breast 
cancer in younger women, it is important to note that more work is needed to fully 
understand the total economic burden of breast cancer in this population. For example, 
missing from the collection of papers in this issue are mortality and non-medical (financial 
burden) costs. Although a recent study has reported on the economic impact associated with 
premature death in younger women, an update of this study may be needed, specifically for 
women aged 18–44 years.7 In addition, studies on financial burden such as out-of-pocket/
family income spent during medical care, transportation costs to and from medical care 
treatments, and child/dependent care costs, particularly for women at childbearing age are 
not included in this compilation of papers and are currently lacking in the literature.
In addition to economic burden studies, other aspects of economic analysis such as 
economic evaluation studies on interventions to prevent breast cancer in this population are 
lacking. This aspect of economic analysis compares the costs and health outcomes of an 
intervention (e.g., breastfeeding) with those of an alternative intervention (usually the 
current standard of practice). It does not describe clinical effectiveness, but addresses 
questions such as whether additional health benefits can be obtained from the same amount 
of resources or whether the same benefit can be achieved with fewer resources by use of 
another intervention. This type of analysis calls for the use of cost-effectiveness or cost-
utility analyses of which the data reported in this issue would be used as input variables.
The burden of cancer affects nearly everyone in the U.S. Although many younger women 
are surviving breast cancer, these women have substantial medical expenditures among both 
those privately or publically insured, have lower HRQoL, and have lost employment and 
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home productivity because of poor health. These findings may be difficult to identify in 
aggregate studies. Therefore, it is the authors’ hope that the findings reported in this theme 
issue fill some of the knowledge gaps and provide awareness regarding the economic burden 
of breast cancer among younger women.
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Illustration of the conceptual framework of the articles in this theme issue.
Note: # means the number of articles in the theme issue. Health state utility (HSU) values 
are scaled to a single 0 (dead) to 1 (best health) cardinal index. HSU is a special health-
related quality of life measure that represents global health-related well-being, is based on 
preference-based tradeoffs, and is used in economic evaluations to value improvements in 
morbidity and mortality from interventions (e.g., quality-adjusted life-years).
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